Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 1

2(33.3%)

Phase 4

1(16.7%)

6Total

Phase 2(3)

Phase 1(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01656226Phase 4Unknown

Long Term Efficacy and Safety of Eryfotona AK-NMSC® in Patients With Actinic Keratosis

Role: lead

NCT00781053Phase 2Completed

Open Label Extension (OLE) for the Patients Treated in the ISD002-P144-07 Study

Role: lead

NCT00574613Phase 2Completed

Efficacy and Safety Study of p144 to Treat Skin Fibrosis in Systemic Sclerosis

Role: lead

NCT01360749Phase 2Completed

Efficacy and Safety of Lambdalina (Lidocaine Cream) Versus Placebo as an Anesthetic for Laser Hair Removal

Role: lead

NCT00656825Phase 1Completed

Tolerability and Bioavailability of the P144 Peptide Inhibitor of TGF-β1 After Topical Administration in Healthy Volunteers

Role: lead

NCT00578370Phase 1Completed

Efficacy and Tolerability Study of Topical Ciclosporin in a Psoriasis Plaque Test

Role: lead

All 6 trials loaded